CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Jazz bets on epilepsy again by acquiring Actio for $820M upfront

Positive
AI Analysis

Summary

Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments for an ultra-rare epilepsy drug, further expanding its epilepsy portfolio.

Importance:7/10
Sentiment:
0.60
M&Aepilepsyultra-rare diseaseacquisition
Related Companies

Read the original article

Published by Endpoints News on August 10, 2026 1:45 PM

Read Original